Abstract
Continuous hemodiafiltration (CHDF) is regarded as an effective treatment for fulminant hepatitis and acute hepatic failure. We evaluated the efficacy of maintenance hemodiafiltration (MHDF) in five end-stage renal failure (ESRF) patients with liver cirrhosis. MHDF was effective in improving the hepatic encephalopathy and general condition. After MHDF therapy, blood NH3 levels decreased, blood albumin levels increased and were kept above 3.5g/dl, and Fisher's molar ratio increased. From these results, it is suggested that MHDF for ESRF patients with liver cirrhosis is an effective therapy for not only for prolonging survival periods but also for improving the quality of life.
